Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GC Pharma
The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.
Oral antivirals make progress in Asia as Japan issues emergency approval to Merck's Lagevrio in a matter of weeks and South Korea clears Pfizer's contender Paxlovid. Vaccines also move forward in both countries with deals for boosters, new supply agreements and the advancement of home-grown candidates.
CanBridge public listing is expected to generate much needed funding and spotlights a largely untapped but challenging segment.
Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Ceragem Medisys
- Green Cross LabCell
- Green Cross Corporation